BioCentury
ARTICLE | Company News

Millennium antibody deal with BZL

April 11, 2001 7:00 AM UTC

MLNM will use BZL Biologics' humanized J591 antibody to develop and commercialize both immunotoxin and radiolabeled antibodies targeting Prostate Specific Membrane Antigen ( PSMA). MLNM and BZL (New Y...